Researchers from Medizinische Hochschule Hannover and collaborators thus aimed to elucidate signaling adaptations following MAPK pathway inhibition in BRAFV 600E mutant cholangiocarcinoma (CCA) by generating a BRAF V600E-driven model of CCA.

Researchers from Beijing University of Chinese Medicine described the role of TRIM54 in cirrhosis progression using two independent animal models of chronic liver injury – a DEN-induced rat model and a CCl4-induced mouse model of liver cirrhosis.

Researchers from Rectify Pharmaceuticals Inc. presented preclinical efficacy data on RTY-406, a novel dual-acting ABCB4/MDR3 and ABCB11/BSEP modulator, in animal models of primary sclerosing cholangitis.